A pilot study of combination therapy of radiation and local administration of OK-432 for esophageal cancer. Five-year survival and local control rate

A pilot study to investigate the occurrence of 10 mycotoxins (deoxynivalenol, DON; 3-acetyldeoxynivalenol, 3-ADON; 15-acetyldeoxynivalenol, 15-ADON; fusarenon-X, FUS-X; diacetoxyscirpenol, DAS; nivalenol, NIV; neosolaniol, NEO; zearalenone, ZON; zearalanone, ZAN; T-2 toxin, T-2; and HT-2 toxin, HT-2) in esophageal cancer patients was performed with the urinary biomarkers approach in Golestan, Iran. Urine multimycotoxin analysis was performed by dispersive liquid–liquid microextraction and gas chromatography–tandem mass spectrometry (GC–MS/MS) analysis, and values were normalized with urinary creatinine (μg/g). Four mycotoxins, namely NEO (40%), HT-2 (17.6%), DON (10%), and HT-2 (5.8%), were detected in the analyzed urine samples. DON was only detected in the control group (5.09 μg/g creatinine), while T-2 (44.70 μg/g creatinine) was only present in the esophageal cancer group. NEO and HT-2 were quantified in both control and case groups, showing average of positive samples of 9.09 and 10.45 μg/g creatinine for NEO and 16.81 and 29.09 μg/g creatinine for HT-2, respectively. Mycotoxin co-occurrence was observed in three samples as binary (NEO/HT-2 and T-2/HT-2) and ternary (DON/NEO/HT-2) combinations, reaching total concentrations of 44.58, 79.13, and 30.04 µg/g creatinine, respectively. Further investigations are needed to explore a causal association between mycotoxin contamination and esophageal cancer. For this pilot study in Golestan, the low sample size was a very limiting factor.

Download Full-text

Carbon Ion Radiotherapy for Oligo-Recurrence in the Lung

Pulmonary Medicine ◽

10.1155/2013/219746 ◽

2013 ◽

Vol 2013 ◽

pp. 1-6 ◽

Cited By ~ 5

Author(s):

Naoyoshi Yamamoto ◽

Mio Nakajima ◽

Hirohiko Tsujii ◽

Tadashi Kamada

Keyword(s):

Colorectal Cancer ◽

Lung Cancer ◽

Overall Survival ◽

Survival Rate ◽

Local Control ◽

Local Control Rate ◽

Carbon Ion Radiotherapy ◽

Overall Survival Rate ◽

Carbon Ion ◽

Metastatic Lung

The clinical results after carbon ion radiotherapy for the metastatic lung tumors believed to be in the state of oligo-recurrence were evaluated. One hundred and sixteen lesions in 91 patients with lung cancer metastasis were treated with carbon ion radiotherapy at our institute from April 1997 to February 2011. Regarding the prescribed dose, total dose ranged between 40 gray equivalents (GyE) and 80 GyE, and fraction size ranged from 1 to 16 fractions. After a median followup period of 2.3 years (range, 0.3–13.1 years), the statistical overall survival rate and local control rate were 71.2% and 91.9% at 2 years after treatment, respectively. Treatment-related side effects were not a clinical problem. When classified by the primary organ, there were 49 cases of lung cancer, 20 cases of colorectal cancer, and 22 cases of others. The overall survival rate and local control rate for lung metastasis cases from lung cancer at 2 years after treatment were 81.5% and 92.4%, respectively, and 65.0% and 92.0% regarding lung metastasis from colorectal cancer. Carbon ion beam therapy for the metastatic lung tumors is a safe therapy, and the therapeutic effect is comparable to the outcome obtained from reported surgical resections.

Download Full-text

Safety assessment of autologous stem cell combination therapy in patients with decompensated liver cirrhosis: a pilot study

Journal of Clinical and Experimental Hepatology ◽

10.1016/j.jceh.2021.03.010 ◽

2021 ◽

Author(s):

Mithun Sharma ◽

Pavan Kumar Pondugala ◽

Shashidhar Jaggaihgari ◽

Sasikala Mitnala ◽

Vemula Venkata Krishna ◽

...

Keyword(s):

Liver Cirrhosis ◽

Stem Cell ◽

Pilot Study ◽

Combination Therapy ◽

Safety Assessment ◽

Decompensated Liver Cirrhosis

Download Full-text

Significantly Improved Local Control With the Use of Cesium-131 Brachytherapy in High-Risk and Recurrent Head and Neck (HN) Cancers: Long-Term Results of a Pilot Study

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2014.05.1582 ◽

2014 ◽

Vol 90 (1) ◽

pp. S517

Author(s):

A. Pham ◽

S. Arora ◽

A. Wernicke ◽

D.I. Kutler ◽

K. William ◽

...

Keyword(s):

Pilot Study ◽

High Risk ◽

Head And Neck ◽

Local Control ◽

Long Term Results ◽

Recurrent Head

Download Full-text

Preliminary results of linear accelerator radiosurgery for acoustic schwannomas

Journal of Neurosurgery ◽

10.3171/jns.1996.85.6.1013 ◽

1996 ◽

Vol 85 (6) ◽

pp. 1013-1019 ◽

Cited By ~ 79

Author(s):

William M. Mendenhall ◽

William A. Friedman ◽

John M. Buatti ◽

Francis J. Bova

Keyword(s):

Stereotactic Radiosurgery ◽

Local Control ◽

Linear Accelerator ◽

Local Control Rate ◽

Magnetic Resonance Images ◽

High Rate ◽

Content Type ◽

Treatment Volume ◽

Fine Print

✓ In this paper the authors evaluate the results of linear accelerator (LINAC)—based stereotactic radiosurgery for acoustic schwannomas. Fifty-six patients underwent LINAC-based stereotactic radiosurgery for acoustic schwannomas at the University of Florida between July 1988 and November 1994. Each patient was followed for a minimum of 1 year or until death; no patient was lost to follow up. One or more follow-up magnetic resonance images or computerized tomography scans were obtained in 52 of the 56 patients. Doses ranged between 10 and 22.5 Gy with 69.6% of patients receiving 12.5 to 15 Gy. Thirty-eight patients (68%) were treated with one isocenter and the dose was specified to the 80% isodose line in 71% of patients. Fifty-five patients (98%) achieved local control after treatment. The 5-year actuarial local control rate was 95%. At the time of analysis, 48 patients were alive and free of disease, seven had died of intercurrent disease, and one was alive with disease. Complications developed in 13 patients (23%). The likelihood of complications was related to the dose and treatment volume: 10 to 12.5 Gy to all volumes, three (13%) of 23 patients; 15 to 17.5 Gy to 5.5 cm3 or less, two (9%) of 23 patients; 15 to 17.5 Gy to more than 5.5 cm3, five (71%) of seven patients; and 20 to 22.5 Gy to all volumes, three (100%) of three patients. Linear accelerator—based stereotactic radiosurgery results in a high rate of local control at 5 years. The risk of complications is related to the dose and treatment volume.

Download Full-text